ScandiDos registers new share issue of 12.3 MSEK
The issue of 14,252,771 shares increases the share capital and Spore Invest increases its ownership to 44%.
See the latest news and media coverage for ScandiDos. We track all announcements, press releases, and industry mentions in real time, all in one place.
Radiotherapy quality assurance solutions provider
scandidos.comLast updated
In short: ScandiDos raised $1.2M through a rights issue, launched the Delta4 SRS Pro, and appointed Anders Murman as acting CEO.
The issue of 14,252,771 shares increases the share capital and Spore Invest increases its ownership to 44%.
The issue provides the company with 12.8 MSEK before costs with a subscription rate of 100 percent.
The issue provides 12.8 MSEK before costs and aims to launch a new product for stereotactic radiation therapy.
The issue comprises a maximum of 14,252,771 shares at a subscription price of SEK 0.90 per share.
The medical technology company Scandidos has released the information document for its rights issue of 12,8 Mkr. Emissionsguiden raises two flags.
The medical technology company Scandidos has decided on a rights issue that can provide the company with SEK 12.8 million before costs. Emissionsguiden initiates its coverage.
ScandiDos AB announces that Gustaf Piehl is stepping down as Chief Executive Officer at his own request. The Board has appointed Anders Murman as Acting...
Scandios reduces its turnover and turns to loss, the company reports. The radiation therapy company believes that the lower quarterly result is a consequence of...
Track ScandiDos and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Browse news for competitors to ScandiDos and other trending companies.